Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
Coaching and Behavioral Support: WeightWatchers includes behavioral support tools and coaching that are designed to help you build habits that last well beyond your time on medication
Its primary functions include stimulating insulin release from the pancreas, suppressing glucagon (a hormone that raises blood sugar), slowing gastric emptying, and signalling satiety (fullness) to the brain
Low-density lipoprotein cholesterol (LDL-C) reductions are more modest, generally in the range of 2-10%, though some patients experience more substantial decreases
.png)
